A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.

S, Hipp; YT, Tai; D, Blanset; P, Deegen; J, Wahl; O, Thomas; B, Rattel; PJ, Adam; KC, Anderson; M, Friedrich

doi:10.1038/leu.2016.388

Public

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo.

Shared by NobleBlocks on Dec 27, 2016 • 12:00 AM UTC

Authors:

Hipp S

Tai YT

Blanset D

Abstract

B-cell maturation antigen (BCMA) is a highly plasma cell-selective protein that is expressed on malignant plasma cells of multiple myeloma (MM) patients and therefore is an ideal target for T-cell redirecting therapies. We developed a bispecific T-cell engager (BiTE) targeting BCMA and CD3ɛ (BI 8369...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!